Recent Updates
Recently added Catalysts
OKUR Positive Sentiment

OnKure Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for its Mutant Selective PI3Kα inhibitor, OKI-219

Key Takeaway: OnKure, Inc. has received FDA clearance for its Investigational New Drug application for OKI-219, a selective PI3Kα H1047R inhibitor. This drug targets a common mutation found in various cancers, particularly breast cancer. The company plans to initiate a first-in-human trial in early 2024, focusing on patients with advanced solid tumors harboring this mutation. OKI-219 demonstrates strong efficacy with minimal toxicity, indicating a promising therapeutic option.

Market Sentiment Analysis

POSITIVE FACTORS

  • FDA clearance for IND application of OKI-219.
  • Potential best-in-class selective inhibitor with strong efficacy.
  • No observed toxicities related to wild-type PI3Kα inhibition.
  • Plans for first-in-human clinical trial in early 2024.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+127%
120-day peak, hindsight
Typical move
13.8%
average across 2 past catalysts
Cash runway
~51 mo
Minimal dilution risk
Lead asset
OKI-179+ binimetinib
Phase 2 · RAS Mutation

Full Press Release Details

BOULDER, Colorado – January 4, 2024 – OnKure, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of OKI-219, a potential best-in-class, mutant selective PI3Kα H1047R inhibitor, for clinical evaluation. H1047R is the most common mutation in PI3Kα, being found in 15% of breast cancer and 4% of cancers overall.
There is a significant need for improved therapies targeting PI3Kα with safer and more effective drugs. OKI-219 is a highly selective inhibitor of PI3Kα H1047R , with over 100-fold selectivity for the wild-type enzyme, potentially sparing on-target toxicities that arise from inhibition of the wild-type form of the protein in normal tissues. OKI-219 shows strong, single-agent activity, including regressions at low doses in multiple PI3Kα H1047R xenograft models that are heterozygous for PI3Kα H1047R , the most common profile seen clinically for this mutation, and supporting the potential activity of highly mutant-selective inhibitors. Notably, in preclinical models, OKI-219 shows no evidence of toxicities related to PI3Kα wild-type inhibition as measured by markers of hyperglycemia, even at doses that are >15x higher than minimally active doses for antitumor activity.
Mutational activation of PI3Kα is associated with lower activity of both estrogen receptor (ER)-targeted and HER2-targeted agents in breast cancer. OKI-219 shows synergistic activity in combination with selective estrogen receptor degraders (SERDs), overcoming SERD resistance and driving strong regressions. Similarly, the combination of OKI-219 + tucatinib drives strong regressions in models of HER2+/ PI3Kα H1047R breast cancer that are resistant to HER2- inhibitors.
OnKure plans to initiate a first-in-human clinical trial, OKI-219-101 (PIKture-01), in the first quarter of 2024 that will include a dose escalation in patients with advanced solid tumors harboring the PI3Kα H1047R mutation. Subsequent evaluation of OKI-219 in combination with the SERD fulvestrant in ER+/ PI3Kα H1047R advanced breast cancer, and with the HER2-monoclonal antibody trastuzumab in HER2+/ PI3Kα H1047R advanced breast cancers will follow.
About PI3Kα and OKI-219
PI3Kα is the most frequently mutated oncogene in cancers, and PI3Kα H1047R is the most common mutation in this gene, being found in 15% of breast cancer and 4% of cancers overall. While novel drugs targeting PI3Kα have been approved, the lack of mutant selectivity of these therapeutics drives considerable on-target toxicity by inhibiting the normal version of this protein in various tissues. To address this challenge, OnKure is discovering and developing a platform of highly mutant-selective PI3Kα inhibitors with the goal of improving efficacy and safety with molecules that fully inhibit the mutant oncogene while sparing the wild-type enzyme in normal tissues. OKI-219 is a potential best-in-class, orally bioavailable, highly selective inhibitor of PI3Kα H1047R with over 100-fold selectivity for the mutated form of the enzyme compared to wild-type. OnKure believes that the wild-type sparing properties of OKI-219 should significantly improve the activity and safety relative to currently approved agents. OKI-219 is currently in Phase 1 of clinical development in solid tumor patients with PI3Kα H1047R mutations.
About OnKure
OnKure, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a proven structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3Kα H1047R inhibitor, as its lead program. OnKure aims to become the leader in targeting oncogenic PI3Kα and has multiple programs to enable best-in-class targeting of this key oncogene.
For more information about OnKure, visit us at www.onkure.com and follow us on X (formerly known as Twitter) and LinkedIn .

Frequently Asked Questions

What is OKI-219?

OKI-219 is a selective PI3Kα H1047R inhibitor developed by OnKure.

What mutation does OKI-219 target?

OKI-219 targets the PI3Kα H1047R mutation, common in breast cancer.

When will the clinical trial for OKI-219 start?

The first-in-human clinical trial for OKI-219 is set to begin in early 2024.

What are the benefits of OKI-219?

OKI-219 shows strong efficacy with minimal toxicity related to wild-type PI3Kα.

Who is developing OKI-219?

OKI-219 is being developed by OnKure, a clinical-stage biopharmaceutical company.

Last updated: Jan 4, 2024